International journal of clinical oncology
Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.
Tetsuro Ochi, Shinichi Makita, Anna Hiratsuka, Risa Nishiyama, Kimiteru Ito, Akiko Miyagi Maeshima, Wataru Takeda, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Koji Izutsu
Published: 202610.1007/s10147-025-02946-4
Abstract
BACKGROUND: Lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T cell therapy, has demonstrated efficacy in relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, real-world data from commercial settings outside the United States remain…
Preview only. Read the full abstract at the source